To clarify the role of EphA2 in the malignant behavior of RCC such as apoptosis resistance and cellular invasiveness, Annexin-V and modified Matrigel-Boyden chamber assays were performed, respectively. This evidence concerns the gene EPHA2 and renal cell carcinoma.